Lyell Immunopharma (NASDAQ:LYEL) Stock Price Down 4.6%

Lyell Immunopharma, Inc. (NASDAQ:LYEL) dropped 4.6% on Thursday . The company traded as low as $2.26 and last traded at $2.27. Approximately 59,999 shares changed hands during mid-day trading, a decline of 94% from the average daily volume of 1,001,889 shares. The stock had previously closed at $2.38.

Analyst Upgrades and Downgrades

Separately, HC Wainwright lowered their price objective on Lyell Immunopharma from $8.00 to $6.00 and set a “buy” rating on the stock in a research note on Thursday, February 29th.

Lyell Immunopharma Stock Performance

The company’s 50 day simple moving average is $2.28 and its two-hundred day simple moving average is $2.01.

Lyell Immunopharma (NASDAQ:LYEL) last announced its earnings results on Wednesday, February 28th. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.01. Lyell Immunopharma had a negative return on equity of 32.67% and a negative net margin of 180,486.14%. The company had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $4.96 million. On average, sell-side analysts predict that Lyell Immunopharma, Inc. will post -0.81 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Tower Research Capital LLC TRC raised its position in shares of Lyell Immunopharma by 251.9% during the first quarter. Tower Research Capital LLC TRC now owns 10,687 shares of the company’s stock worth $25,000 after acquiring an additional 7,650 shares during the last quarter. Advisor Group Holdings Inc. boosted its stake in shares of Lyell Immunopharma by 3,125.3% in the 4th quarter. Advisor Group Holdings Inc. now owns 7,902 shares of the company’s stock valued at $27,000 after purchasing an additional 7,657 shares during the last quarter. Virtu Financial LLC acquired a new stake in shares of Lyell Immunopharma during the 4th quarter worth approximately $29,000. Ethic Inc. bought a new stake in shares of Lyell Immunopharma during the first quarter worth approximately $30,000. Finally, Vanguard Personalized Indexing Management LLC bought a new position in Lyell Immunopharma in the fourth quarter valued at approximately $31,000. Institutional investors own 66.05% of the company’s stock.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.